{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:44:28Z","timestamp":1790286268096,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Shanghai Ruizhi Medical Technology Co Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Controlling the relapses of scalp psoriasis is a clinical issue.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of a supramolecular active zinc antidandruff hair conditioner in managing scalp psoriasis (SP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicentre randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial enrolled 211 patients with SP between October 2018 and June 2019. The participants were randomized 1 : 1 : 1 to the experimental (supramolecular active zinc antidandruff hair conditioner), placebo (supramolecular hydrogel) or positive control (calcipotriol ointment) group. The primary efficacy endpoint was the disease control rate at the end of the fourth week of treatment, measured using the Investigator\u2019s Global Assessment score.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study included 70, 70 and 71 participants in the experiment, control and placebo groups, respectively. The disease control rates of SP at the end of week 4 of treatment in the full-analysis set (FAS) were 39%, 25% and 37% in the experimental, placebo and control groups. The margin of superiority between the experimental and placebo groups was &amp;gt; 0 [96% confidence interval (CI) 13.22% (0.43% to \u221e)] in the FAS. The experimental group was superior to the placebo group. The noninferiority margin between the experiment and control groups was &amp;gt; \u201315% [96% CI \u20131.43% (\u201314.91% to \u221e)] in the FAS. The experimental group was not inferior to the control group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Supramolecular active zinc antidandruff hair conditioner was helpful for the treatment of SP, and it has good clinical efficacy in maintaining therapeutic effect and assisting in preventing the recurrence of psoriasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llad168","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T14:10:02Z","timestamp":1683209402000},"page":"1138-1144","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of supramolecular active zinc in the treatment of scalp psoriasis: a multicentre, randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-1198","authenticated-orcid":false,"given":"Chen","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019 an , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, General Hospital of Ningxia Medical University , Yinchuan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, West China Hospital, Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of China Medical University , Shenyang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichao","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Strategic Support Force Specialty Medical Center (306 Hospital of PLA) , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5842-8080","authenticated-orcid":false,"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xijing Hospital, The Fourth Military Medical University , Xi\u2019 an , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"2023091916470152500_llad168-B1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/annrheumdis-2018-214065","article-title":"Prevalence and incidence of psoriasis and psoriatic arthritis","volume":"78","author":"Sewerin","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023091916470152500_llad168-B2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028116","article-title":"Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort","volume":"9","author":"Egeberg","year":"2019","journal-title":"BMJ Open"},{"key":"2023091916470152500_llad168-B3","doi-asserted-by":"crossref","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2023091916470152500_llad168-B4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","article-title":"Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management","volume":"11","author":"Mosca","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023091916470152500_llad168-B5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023091916470152500_llad168-B6","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023091916470152500_llad168-B7","first-page":"309","article-title":"Quality of life in patients with scalp psoriasis","volume":"150","author":"Zampieron","year":"2015","journal-title":"G Ital Dermatol Venereol"},{"key":"2023091916470152500_llad168-B8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023091916470152500_llad168-B9","first-page":"667","article-title":"Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition)","volume":"52","author":"Committee on Psoriasis, Chinese Society of Dermatology","year":"2019","journal-title":"Chin J Dermatol"},{"key":"2023091916470152500_llad168-B10","first-page":"CD009687","article-title":"Topical treatments for scalp psoriasis","volume":"2","author":"Schlager","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2023091916470152500_llad168-B11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1203475416655705","article-title":"2016 Addendum to the Canadian Guidelines for the management of plaque psoriasis 2009","volume":"20","author":"Canadian Psoriasis Guidelines Addendum C.","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"2023091916470152500_llad168-B12","first-page":"275","article-title":"Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream","volume":"11","author":"Alora-Palli","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"2023091916470152500_llad168-B13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1067\/mjd.2001.117849","article-title":"Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo","volume":"45","author":"Warner","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2023091916470152500_llad168-B14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/0019-5154.62734","article-title":"Dandruff: the most commercially exploited skin disease","volume":"55","author":"Ranganathan","year":"2010","journal-title":"Indian J Dermatol"},{"key":"2023091916470152500_llad168-B15","first-page":"68","article-title":"Study on the efficacy and safety of scalp care products containing zinc pyrithione and salicylic acid in improving seborrheic dermatitis","volume":"26","author":"Tong","year":"2017","journal-title":"Chin J Aest Med"},{"key":"2023091916470152500_llad168-B16","first-page":"187","article-title":"Treatment of localized psoriasis with a topical formulation of zinc pyrithione","volume":"20","author":"Sadeghian","year":"2011","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"2023091916470152500_llad168-B17","first-page":"223","article-title":"Guidelines for diagnosis and treatment of psoriasis in China","volume":"52","author":"Psoriasis Professional Committee of Dermatology and Venereology Branch of Chinese Medical Association","year":"2019","journal-title":"Chin J Dermatol"},{"key":"2023091916470152500_llad168-B18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"2023091916470152500_llad168-B19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2023091916470152500_llad168-B20","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2017.01.027","article-title":"Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis","volume":"140","author":"Guttman-Yassky","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2023091916470152500_llad168-B21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/pst.1846","article-title":"Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point","volume":"17","author":"Huang","year":"2018","journal-title":"Pharm Stat"},{"key":"2023091916470152500_llad168-B22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s13063-022-06319-4","article-title":"Comparative effectiveness of in-person vs. remote delivery of the common elements treatment approach for addressing mental and behavioral health problems among adolescents and young adults in Zambia: protocol of a three-arm randomized controlled trial","volume":"23","author":"Figge","year":"2022","journal-title":"Trials"},{"key":"2023091916470152500_llad168-B23","first-page":"140","article-title":"Zinc pyrithione: a topical antimicrobial with complex pharmaceutics","volume":"15","author":"Schwartz","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"2023091916470152500_llad168-B24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2133.1988.tb03474.x","article-title":"Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid","volume":"119","author":"Stamatiadis","year":"1988","journal-title":"Br J Dermatol"},{"key":"2023091916470152500_llad168-B25","first-page":"148","article-title":"Observation on the clinical efficacy of zinc pyrithione dandruff shampoo in the treatment of scalp psoriasis vulgaris","volume":"6","author":"Xiong","year":"2019","journal-title":"Electtr J Clin Med Lit"},{"key":"2023091916470152500_llad168-B26","first-page":"258","article-title":"Study on the clinical efficacy of salicylic acid anti dandruff hair conditioner in treating seborrheic dermatitis of scalp","volume":"15","author":"Hu","year":"2021","journal-title":"Dus Monit Contr"},{"key":"2023091916470152500_llad168-B27","first-page":"26","article-title":"Scalp seborrheic dermatitis and dandruff therapy using a herbal and zinc pyrithione-based therapy of shampoo and scalp lotion","volume":"11","author":"Barak-Shinar","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"key":"2023091916470152500_llad168-B28","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2023091916470152500_llad168-B29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3122\/jabfm.2013.06.130055","article-title":"Psoriasis vulgaris: an evidence-based guide for primary care","volume":"26","author":"Kupetsky","year":"2013","journal-title":"J Am Board Fam Med"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad168\/50983986\/llad168.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/10\/1138\/51685209\/llad168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/10\/1138\/51685209\/llad168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T17:08:51Z","timestamp":1695143331000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/10\/1138\/7152251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5,4]]},"published-print":{"date-parts":[[2023,9,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad168","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,5,4]]}}}